I've worked as a registered respiratory therapist for over 10 years. I've seen the disparities in healthcare first hand while serving an underprivileged community in St. Louis. I was diagnosed with primary biliary cholangitis at the end of 2019 when I was just 31 years old. Shortly after my diagnosis, the world shut down due to the Covid-19 pandemic. I never imagined I would be working as a Respiratory Therapist during a respiratory pandemic. I saw more death in my time caring for patients in a Covid ICU than in my entire career caring for deathly ill patients. Eventually, I had to give up my love for critical care and start prioritizing myself. I switched to an outpatient setting in respiratory and began my mental health healing. It was during this time I felt a call for patient advocacy. I started my own PBC only support group on Facebook in November 2023. My support group has over 3,000 worldwide patients with PBC. My goal is to foster a safe environment for friendship and support. For more information please search "Life with PBC 💙 Primary Biliary Cholangitis" to join. At the end of 2023, I was asked to join Rare Disease Advisor as a patient columnist. I am now the PBC Ambassador for their PBC Companion as well. In 2024 I joined the Food and Drug Administration in the U.S. as a special government employee. My role is the PBC patient representative. I was part of the Ocalivia committee panel that took place in September 2024. In 2025, I joined Friends of the PBC Foundation as the Director of Patient Relations. We had our inaugural Patient Conference in September 2025 with great success. In February of 2026, I stepped up to be the President of the US nonprofit Friends of the PBC Foundation. At the end of 2025, I also joined Health Union as a PBC Patient Leader for primarybiliarycholangitis.net. Being a healthcare professional and a rare disease patient gives me an interesting voice and experience. I am looking forward to continuing my journey as a strong advocate for patients with Primary Biliary Cholangitis.
The rare disease ecosystem is undergoing a strategic shift from general awareness to actionable
advocacy. While patient voices are increasingly invited into drug development, regulators and HTA
bodies still struggle to translate lived experience into recognized evidence.
This panel examines how specialized rare disease media—specifically Rare Disease
Advisor—transforms patient narratives into actionable “human data.” Through curated patient
columns, RDA creates a validated, public record of patient-reported outcomes that informs endpoint
development, supports PFDD initiatives, and shortens the diagnostic odyssey. Panelists will explore
how media can serve as a strategic partner in clinical development, regulatory decision-making, and
early disease recognition.